Abstract: The disclosure relates to a pectin-adriamycin conjugate, and discloses a preparation method and use of the conjugate above. The pectin-adriamycin conjugate of the disclosure has a completely new chemical structure and can be accumulated in a malignant tumor tissue for a long time with a high concentration in a targeting manner so as to achieve the purposes of enhancing effects and reducing toxicity, and the indications are chemotherapies of various solid malignant tumors.
Type:
Grant
Filed:
June 18, 2019
Date of Patent:
March 7, 2023
Assignee:
SICHUAN YINGRUI PHARMACEUTICAL TECHNOLOGY COMPANY
Abstract: The disclosure relates to a pectin-adriamycin conjugate, and discloses a preparation method and use of the conjugate above. The pectin-adriamycin conjugate of the disclosure has a completely new chemical structure and can be accumulated in a malignant tumor tissue for a long time with a high concentration in a targeting manner so as to achieve the purposes of enhancing effects and reducing toxicity, and the indications are chemotherapies of various solid malignant tumors.
Type:
Application
Filed:
June 18, 2019
Publication date:
April 14, 2022
Applicant:
Sichuan Yingrui Pharmaceutical Technology Company
Abstract: The present invention provides a nanocarbon-iron composite system which is a composite structure formed by interaction of acid-treated nanocarbon serving as a carrier, with and ferrous ions and/or ferric ions in an iron salt. In an in-vitro experiment and an animal experiment, the nanocarbon-iron composite system of the present invention shows a very efficient inhibition effect on solid tumors containing liver cancer, breast cancer and cervical cancer and has an excellent targeting property. Accordingly, the present invention further provides a preparation method of the nanocarbon-iron composite system, use of the nanocarbon-iron composite system in preparation of a drug for treating solid tumors, and a suspension for injection based on the nanocarbon-iron composite system.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
February 1, 2022
Assignee:
SICHUAN YINGRUI PHARMACEUTICAL TECHNOLOGY COMPANY